<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03460548</url>
  </required_header>
  <id_info>
    <org_study_id>TOGA-CT-1501</org_study_id>
    <nct_id>NCT03460548</nct_id>
  </id_info>
  <brief_title>REMOGEN® Omega Versus Cationorm® in the Treatment of Patients Suffering From Dry Eye</brief_title>
  <official_title>A Multicentre Randomized Trial Comparing the Efficacy and Safety of REMOGEN® Omega Versus Cationorm® in the Treatment of Patients Suffering From Dry Eye</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TRB Chemedica</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TRB Chemedica</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The efficacy and safety of Remogen® Omega in the treatment of dry eye signs and symptoms will
      be investigated in comparison to Cationorm®.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low recruitment rate
  </why_stopped>
  <start_date type="Actual">March 30, 2018</start_date>
  <completion_date type="Actual">June 12, 2019</completion_date>
  <primary_completion_date type="Actual">April 16, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>OSSF</measure>
    <time_frame>Day 28</time_frame>
    <description>Ocular surface staining with fluorescein (OSSF)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Dry Eye</condition>
  <arm_group>
    <arm_group_label>Remogen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cationorm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Remogen</intervention_name>
    <description>instil 1 drop of the product in each eye, 4 times per day</description>
    <arm_group_label>Remogen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cationorm</intervention_name>
    <description>instil 1 drop of the product in each eye, 4 times per day</description>
    <arm_group_label>Cationorm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  With at least a 3-month documented history of bilateral dry eye

          -  With a score of ocular surface staining with fluorescein (OSSF) ≥ 4 and ≤ 9 on the
             Oxford scale

          -  With at least one objective sign of tear deficiency

          -  With Ocular Surface Disease Index (OSDI) score of ≥ 18

        Exclusion Criteria:

          -  Refractive surgery within 12 months prior to selection

          -  Any other ocular surgery or ocular trauma within 6 months prior to selection

          -  Systemic or local use of one of the following medications: glucocorticosteroids,
             cyclosporine A, antibiotics, NSAIDs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christophe Baudouin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quinze-Vingts Hospital, Paris, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quinze-Vingts Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 28, 2018</study_first_submitted>
  <study_first_submitted_qc>March 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2018</study_first_posted>
  <last_update_submitted>April 16, 2020</last_update_submitted>
  <last_update_submitted_qc>April 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

